ArticleEJNMMI physics2022
Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for
Article in EJNMMI physics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Cross-Modality Deep Learning Denoising for Low-Dose μSPECT: Transfer of PET-Trained U‑Net and Diffusion Models.Chemical & biomedical imaging · 2026Article
- Personalised Dosimetry in Nuclear Medicine: Bridging Physics, Biology and AI for Next Generation Radiopharmaceutical Therapy.Nuclear medicine and molecular imaging · 2026Review
- Multiple vertebrae improves precision in image-based bone marrow absorbed dose estimation in [EJNMMI physics · 2026Article
- A Phase 0 Imaging Trial of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Review
- Towards practical radiopharmaceutical treatment planning: a review of dosimetry simplification techniques.Theranostics · 2026Review
- Automatic bone marrow segmentation for precise [Medical physics · 2025Article
- On the reduction of imaging time-points for dosimetry in radionuclide therapy.EJNMMI physics · 2025Article
- Dealing with radiation risks in systemic cancer treatment: Perspectives of practitioners and patients in French hospitals.PloS one · 2025Article
- A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?EJNMMI physics · 2024Review
- SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Impact of different models based on blood samples and images for bone marrow dosimetry afterEJNMMI physics · 2024Article
- Effect of kilovoltage and quality reference mAs on CT-based attenuation correction inEJNMMI physics · 2024Article
- Article
- Performance study of a 360° CZT camera for monitoringEJNMMI physics · 2023Article
- Specific Uptake in the Bone Marrow Causes High Absorbed Red Marrow Doses During [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Dosimetric impact of 3D motion-compensated SPECT reconstruction for SIRT planning.EJNMMI physics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe number of SPECT/CT time-points is important for accurate patient dose estimation in peptide receptor radionuclide therapy. However, it may be limited by the patient's health and logistical reasons. Here, an image-based dosimetric workflow adapted to the number of SPECT/CT acquisitions available throughout the treatment cycles was proposed, taking into account patient-specific pharmacokinetics and usable in clinic for all organs at risk.
methodsThirteen patients with neuroendocrine tumors were treated with four injections of 7.4 GBq of
resultsAbsorbed doses (in Gy) per cycle available were: 3.1 ± 1.1 (LK), 3.4 ± 1.5 (RK), 4.5 ± 2.8 (L), 4.6 ± 1.8 (S), 0.3 ± 0.2 (bone marrow). There was a significant difference between bone marrow surrogates (L2 to L4 and L1 to L5, Wilcoxon's test: p value < 0.05), and while depicting very doses, all three surrogates were significantly different than dose in background (p value < 0.01). At cycle 1, if the acquisition at 24H is missing and approximated, medians of percentages of dose difference (PDD) compared to the initial tri-exponential function were inferior to 3.3% for all organs. For cycles with one acquisition, the median errors were smaller with a late time-point. For STP-Inter, medians of PDD were inferior to 7.7% for all volumes, but it was shown to depend on the homogeneity of TDRC.
conclusionThe proposed workflow allows the estimation of organ doses, including bone marrow, from a variable number of time-points acquisitions for patients treated with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.